Revolution Medicines Inc. is close to finalizing a lease for 700,000 square feet at Pacific Shores Center in Redwood City, according to reporting from the Silicon Valley Business Journal. The contemplated transaction would significantly expand the biotech company’s footprint in the city, more than doubling its existing local presence as it positions for the commercial rollout of daraxonrasib, a pancreatic cancer treatment that the publication noted could generate billions of dollars in annual revenue.
The space Revolution Medicines is targeting is located at Pacific Shores Center, a 106-acre waterfront office campus situated at the end of Seaport Boulevard on Redwood City’s bayfront. The property has long been recognized as a prominent corporate hub on the Peninsula, with a campus-style environment that has historically attracted major technology and life science users.
Pacific Shores became closely associated with Google after the tech company acquired much of the campus in 2014. Google subsequently used the property as one of its primary Peninsula hubs, reinforcing the campus’s status as a key office location in the region. However, the tech firm has not occupied the campus since July 2024, and the Silicon Valley Business Journal reported that Google has since completed a sale of its holdings there, signaling a change in the property’s ownership and potentially in its future tenant mix.
If completed, the Revolution Medicines lease would mark a notable backfill of space at Pacific Shores following Google’s departure. It would also underscore the continued role of well-located waterfront office and life science campuses in attracting large-scale tenants, even as legacy tech users reassess their regional real estate footprints. The size of the prospective lease suggests a long-term operational commitment by the biotech company to Redwood City as it scales up for product commercialization.
The potential deal comes at a challenging time for the broader Bay Area life science market. The article notes that the region is experiencing a biotech downturn, with a substantial amount of newly delivered lab space struggling to secure tenants. In that context, a 700,000-square-foot lease at a high-profile campus such as Pacific Shores would stand out as a meaningful absorption event within a market that has been grappling with elevated vacancy and slower leasing velocity in new laboratory and R&D facilities.
